Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Bet v 1 mAbs in Birch Allergy
NCT05430919Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN5713, bremzalerbart, atisnolerbart in allergic rhinitis (AR), allergic conjunctivitis (AC), sponsored by Regeneron Pharmaceuticals. Started Aug 2022; status: completed.
02
Drugs
REGN5713bremzalerbartatisnolerbart
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT05430919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430919.